Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin in children and adolescents with heterozygous familial hypercholesterolemia
2006-002616-96Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rosuvastatin in heterozygous familial hypercholesterolemia (HeFH) (4 arms), sponsored by AstraZeneca. Primary endpoints: Percent change in LDL-C from baseline to Week 12 and Percent change in LDL-C from baseline to Week 6. Started Jun 2006; status: completed.
02
Drugs
rosuvastatin
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on 2006-002616-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002616-96.